Treatment

A new study finds that targeted electroacupuncture may help breast cancer survivors improve cognitive function and reduce psychological distress. In a 10-week trial, 35 survivors with symptoms like fatigue, insomnia, and “brain fog” received weekly electroacupuncture. One group was treated at neuropsychiatric-specific acupoints, while a control group received treatment at non-specific points. Patients receiving targeted […]

A new study suggests that the precision cell therapy Orca-T may outperform the current standard treatment, post-transplant cyclophosphamide (PTCy), for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing stem cell transplants. In this retrospective analysis, patients treated with Orca-T showed notably better outcomes than those who received PTCy. Two-year overall survival reached

The Centers for Medicare & Medicaid Services (CMS) has issued a permanent billing code (J9183) for Inlexzo, the first FDA-approved intravesical system delivering gemcitabine directly to the bladder. This change makes billing easier for healthcare providers and helps patients access the therapy more quickly. Inlexzo, approved in September 2025, treats patients with BCG-unresponsive non-muscle invasive

The Phase 3 TORPEdO trial compared intensity-modulated proton therapy (IMPT) with standard intensity-modulated radiation therapy (IMRT) in 205 patients with locally advanced oropharyngeal cancer. Both groups received the same radiation dose and chemotherapy. The study aimed to see if proton therapy could reduce side effects by sparing healthy tissues. IMPT showed a slight functional advantage

The Phase 3 EMERALD-3 trial has shown that a four-drug combination treatment can significantly delay disease progression in patients with unresectable hepatocellular carcinoma (HCC) who are eligible for embolization. The study tested a combination of STRIDE therapy (tremelimumab and durvalumab), lenvatinib, and TACE, compared with TACE alone. Results showed that adding these therapies led to

Recent advances are changing how doctors treat pancreatic cancer and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). For pancreatic cancer, a newer treatment called NALIRIFOX was approved in early 2024 for patients with metastatic disease. This combination therapy has shown improved survival, helping patients live about 11.1 months on average compared to 9.2 months with the previous standard

The Phase 3 Neo-Healer trial has met its main goal, showing that a new treatment combination can improve outcomes for patients with HER2-positive breast cancer. The study found that anbenitamab (KN026) combined with albumin-bound docetaxel led to a significantly higher rate of total pathologic complete response compared with the current standard treatment using trastuzumab, pertuzumab,

The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to WU-CART-007, an off-the-shelf CAR-T therapy for aggressive T-cell blood cancers. Developed at Washington University School of Medicine and licensed to Wugen, the therapy targets T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Early clinical data show a 91% overall response rate, with nearly

Treatment for chronic myeloid leukemia is rapidly advancing in 2026, offering patients more effective and flexible options than ever before, according to Michael J. Mauro. A new generic version of dasatinib marks a key step forward, as it can be taken with common acid-reducing drugs, simplifying treatment for patients with reflux. Other updates include improved

The FDA approved the PD-L1 IHC 22C3 pharmDx test as a companion diagnostic to help identify patients who may benefit from pembrolizumab. In liver cancer, a new antibody called RCT1213 received Orphan Drug Designation for patients with hepatocellular carcinoma who no longer respond to checkpoint inhibitors, highlighting efforts to target the tumor microenvironment. Progress also